



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/658,787 – Conf. #1823 |
| | | | | Filing Date | September 9, 2003 |
| | | | | First Named Inventor | Carl H. JUNE et al. |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | M. Leavitt |
| Sheet | 1 | of | 2 | Attorney Docket Number | 36119.140US2/AM100528 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|-----------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| ML | AA* | US-5,272,082 | 12-21-1993 | Santoli et al. | |
| | AB* | US-5,399,346 | 03-21-1995 | Anderson et al. | |
| | AC* | US-5,443,983 | 08-22-1995 | Ochoa et al. | |
| | AD* | US-5,733,543 | 03-31-1998 | Nabel et al. | |
| | AE* | US-5,738,852 | 04-14-1998 | Robinson et al. | |
| | AF* | US-5,827,642 | 10-27-1998 | Riddell et al. | |
| | AG* | US-5,858,358 | 01-12-1999 | June et al. | |
| ✓ | AH* | US-6,692,964 | 02-17-2004 | June et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|---|---|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | † |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| ML | BA | WO-90/05541 | 05-31-1990 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | | |
| ML | BB | WO-94/12196 | 06-09-1994 | TANOX BIOSYSTEMS, INC. | | |
| | BC | WO-94/29436 | 12-22-1994 | THE UNITED STATES OF AMERICA represented by THE SECRETARY OF THE NAVY | | |
| ML | | | | | | |
| | BD | WO-95/03408 | 02-02-1995 | DANA-FARBER CANCER INSTITUTE | | |
| ML | | | | | | |
| | BE | WO-95/33823 | 12-14-1995 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE NAVY | | |
| ML | | | | | | |
| | BF | WO-95/34320 | 12-21-1995 | REGENTS OF THE UNIVERSITY OF MINNESOTA | | |
| ML | | | | | | |
| | BG | WO-96/01122 | 01-18-1996 | DANA-FARBER CANCER INSTITUTE | | |
| ML | | | | | | |
| | BH | WO-96/02646 | 02-01-1996 | CYTOTHERAPEUTICS, INC. | | |
| ML | | | | | | |
| | BI | WO-96/06942 | 03-07-1996 | MAX-PLANCK- GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. | | |
| ML | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|------------------|---|--------------------|
| Examiner | Cite | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book). | |
| Examiner Signature | Maria G. Leavitt | | Date Considered |
| 5412706 | | | 02-09-2006 |

US1DOCS 5412706v1

| | | | | | |
|--|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449A/B/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/658,787 – Conf. #1823 |
| | | | | Filing Date | September 9, 2003 |
| | | | | First Named Inventor | Carl H. JUNE et al. |
| | | | | Art Unit | 1633 |
| | | | | Examiner Name | M. Leavitt |
| Sheet | 2 | of | 2 | Attorney Docket Number | 36119.140US2/AM100528 |

| Initials | No. ¹ | magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|----------|------------------|--|----------------|
| ML | CA | Cann et al., "High Efficiency Transfection of Primary Human Lymphocytes and Studies of Gene Expression," <i>Oncogene</i> , 3:122-128 (1988) | |
| ML | CB | Coghlan, "Gene Dream Fades Away" <i>New Scientist</i> , 148: 14-15 (1995) | |
| ML | CC | Crystal, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success" <i>Science</i> , 270:404-410 (1995) | |
| ML | CD | Fauser, "Long-Term Expression of Gene Introduction into Normal Human T-Lymphocytes by Retroviral-Mediated Gene Transfer," <i>Journal of Cellular Biochemistry</i> , 45:353-358 (1991) | |
| ML | CE | Finer et al., "kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes," <i>Blood</i> , 83(1):43-50 (1994) | |
| | CF | Guba et al., "Interleukin 3 Gene Induction in Normal Human T Cells Via Stimulation of CD3 and CD28," <i>Clinical Research</i>, 37(4) (1989) | |
| ML | CG | Gunzburg et al., "Virus Vector Design in Gene Therapy" <i>Molecular Medicine Today</i> , 410-417 (1995) | |
| ML | CH | Lowenthal et al., "Tumor Necrosis Factor α Induces Proteins that Bind Specifically to kB-like Enhancer Elements and Regulate Interleukin 2 Receptor α -chain Gene Expression in Primary Human T Lymphocytes," <i>PNAS USA</i> , 86:2331-2335 (1989) | |
| ML | CI | Mastrangelo et al. "Gene Therapy for Human Cancer: An Essay for Clinicians" <i>Seminars In Oncology</i> , 23(1):4-21 (1996) | |
| ML | CJ | Novak et al., "In Vitro Transfection of Fresh Thymocytes and T Cells Shows Subset-Specific Expression of Viral Promoters," <i>Molecular and Cellular Biology</i> , 12:1515-1527 (1992) | |
| ML | CK | Orkin et al. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" pp. 21-22, December (1995) | |
| ML | CL | Park et al., "Transcriptional Regulation of Interleukin 3 (IL3) in Primary Human T Lymphocytes," <i>Journal of Biological Chemistry</i> , 268(9):6299-6308 (1993) | |
| ML | CM | Philip et al., "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Molecular and Cellular Biology</i> , 14:2411-2418 (1994) | |
| ML | CN | Tiberghien et al., "Ganciclovir Treatment of Herpes Simplex Thymidine Kinase-Transduced Primary T Lymphocytes: An Approach for Specific In Vivo Donor T-Cell Depletion After Bone Marrow Transplantation?" <i>Blood</i> , 84(4):1333-1341 (1994) | |
| ML | CO | Verma et al., "Gene therapy-promise, problems, and prospects" <i>Nature</i> , 389:239-242 (1997) | |
| ML | CP | Weiss, "T Lymphocyte Activation", ch. 13, <i>Fundamental Immunology</i> , Second Edition, ed. by WE Paul, Raven Press Ltd., New York, pp. 359-384 (1989) | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|----------------------|-----------------|------------|
| Examiner Signature | <i>Maria Leavitt</i> | Date Considered | 02-09-2006 |
|--------------------|----------------------|-----------------|------------|

5412708

US1DOCS 5412706v1



Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
36119.140US2Application Number
10/658,787Applicant
June et al.Filing Date
September 9, 2003Group Art Unit
1632

Sheet

1

OF

1

U.S. Patent Documents

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|--------------------|------|-------------|-------|----------|-------------------------------|
| ML | 10/828,481 | N/A | June et al. | N/A | N/A | Apr 20, 2004 |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Foreign Patent Documents

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---------------------|--------------------|------|---------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

| | | |
|--|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |

EXAMINER

Maria Deavitt

DATE CONSIDERED

02-09-2006

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609:
Draw Line through citation if not conformance and not considered. Include copy with next
communication to applicant.